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The attention-deﬁcit/hyperactivity disorder (ADHD) treatment literature has been focused on
onset-of-effect and short-term effect size, with little exploration of ADHD symptoms upon
medication discontinuation. The objective of this narrative review and analysis was to better
understand the relapse of ADHD symptoms upon discontinuation of medication treatment in
children, adolescents, and adults with ADHD who have responded to medication treatment and
to explore differences among different medications in maintaining treatment response.
Randomized withdrawal studies of dexmethylphenidate hydrochloride (d-MPH), methylpheni-
date modiﬁed-release (MPH-LA), lisdexamphetamine dimesylate (LDX), guanfacine extended-
release (GXR), and atomoxetine (ATX) in both children/adolescents and adults with ADHD were
reviewed. The percentage of relapse was signiﬁcantly higher and the time-to-relapse
signiﬁcantly shorter with placebo compared to active treatment in patients who were
previously stable on 5 weeks to 1 year of active treatment, suggesting clinically signiﬁcant
beneﬁt with continued long-term pharmacotherapy. However, percentage of relapse at
each time point studied after discontinuing stimulants and GXR appears substantially higher
than observed when discontinuing ATX, suggesting longer maintenance of response aftero.2015.06.003
CNP. All rights reserved.
ate Center, Indianapolis, IN, USA. Tel.: +1 713 592 0912.
com (H. Upadhyaya).
J. Buitelaar et al.1612discontinuing ATX than after stimulants and GXR. Additionally, slope of relapse percentages
over time appears to be more rapid with stimulants or GXR than with ATX. These differences in
maintenance of response among ATX, GXR, and stimulants may reﬂect differences in
mechanisms of action and persistence of the medication effect. Alternatively, they may be
due to methodological differences, including study design and response/relapse deﬁnitions.
Continued investigation is needed regarding factors that affect risk of symptom relapse upon
discontinuation of pharmacotherapy.
& 2015 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Attention-deﬁcit/hyperactivity disorder (ADHD) is a chronic
disorder, lasting from childhood into adulthood in approxi-
mately two-thirds of patients (Faraone et al., 2006;
Goodman, 2013; Pliszka, 2007; Simon et al., 2009). The
ADHD treatment literature has been focused on onset of
effect and short-term efﬁcacy effect size, but very little
related to ADHD symptoms upon medication discontinuation
has been explored. Treatment rates of ADHD decline sharply
from childhood through young adulthood, but the functional
impairment often persists (Robb and Findling, 2013).
Patients who do continue treatment of ADHD may have
planned or unplanned drug “holidays” (e.g., breaks from
medication on weekends or over summer break from school
or work). However, there is a lack of information about how
long to continue treatment for patients who are responding
to treatment and what should be expected upon medication
discontinuation after long-term medication treatment in
patients with ADHD. Therefore, maintenance of response
and relapse upon discontinuation may be important issues to
consider in ADHD treatment.
Until recently, little information about relapse of ADHD
symptoms following discontinuation of treatment has been
available. The most widely used pharmacological treat-
ments for ADHD are the stimulants methylphenidate (MPH)
and amphetamine, and nonstimulants atomoxetine (ATX),
guanfacine, and clonidine (Kooij et al., 2010). Atomoxetine,
a selective norepinephrine reuptake inhibitor, is a nonsti-
mulant medication approved for the treatment of ADHD in
pediatric and adult patients in many countries. Maintenance
of response with ATX has been demonstrated in pediatric
(Buitelaar et al., 2007; Michelson et al., 2004) and adult
patients (Upadhyaya et al., 2013). Recent studies have also
examined maintenance of response with stimulants (Arnold
et al., 2004; Coghill et al., 2014) and the nonstimulant
guanfacine (Newcorn et al., 2014) in pediatric patients, and
with stimulants in adult patients (Biederman et al., 2010;
Brams et al., 2012; Buitelaar et al., 2012; Huss et al., 2014).
With the availability of these recent data, the maintenance
of response and relapse with ATX and other medications can
be explored.
The objective of this narrative review and analysis was to
better understand the relapse of ADHD symptoms upon
discontinuation of medication treatment in children, ado-
lescents, and adults with ADHD who have responded to
medication treatment and to explore differences among
medications in maintaining treatment response.2. Experimental procedures
This study consisted of a review of maintenance of response
summary results in published studies in children, adoles-
cents, and adults who responded to treatment with stimu-
lants and nonstimulants (Table 1); and an exploratory
analysis of data from ATX maintenance of response studies.
2.1. Literature review
The electronic databases Medline, PsycINFO, and Embase
were searched for articles published between January 1980
and July 2014. This review analyzed maintenance of
response studies in children/adolescents and adults after
treatment with stimulants and nonstimulants. The following
keywords were searched: ADHD, relapse, and withdrawal.
Studies were limited to human, randomized, controlled
trials published in peer-reviewed journals in English. The
titles and abstracts of the articles obtained through this
systematic literature search were screened for eligibility
(48 total eligible abstracts were reviewed for inclusion;
Supplemental Figure 1). Only those articles that examined
maintenance of response in patients with ADHD after
response to treatment with stimulants and nonstimulants
were inspected in detail for inclusion.
Efﬁcacy data were compiled from 9 maintenance clinical
trials, 4 in children and 5 in adults, diagnosed with ADHD
according to Diagnostic and Statistical Manual of Mental
Disorders (DSM), 3rd Edition (DSM-III) or 4th Edition (DSM-IV)
criteria. Trial characteristics, relapse rate percentages, and
time-to-relapse in each study were examined. A summary of
the studies including the characteristics of patients is
provided in Table 1. Patient characteristics were similar
between studies.
2.2. Studies in children and adolescents
In pediatric patients, 4 studies were identiﬁed – including
one study each using ATX (Buitelaar et al., 2007; Michelson
et al., 2004), lisdexamfetamine dimesylate (LDX) (Coghill
et al., 2014), dexmethylphenidate hydrochloride (d-MPH)
(Arnold et al., 2004), and guanfacine extended-release
(GXR) (Newcorn et al., 2014) (Table 2).
The ATX study was a global multicenter study in children
and adolescents who responded to an initial 12-week, open-
label treatment with ATX (1.2–1.8 mg/kg/day) and were
then randomized to continued ATX treatment or placebo for
Table 1 Summary of ADHD withdrawal studies – patient characteristics.
Study N Sites Mean age
(years)
Sex ADHD
subtype
Baseline at
study entry
ADHD-RS-IV
total score
Baseline at
randomization
ADHD-RS-IV
total score
Baseline
at study
entry
CGI-S
score
Baseline at
randomization
CGI-S score
Children/adolescents
ATX (First
randomiza-
tion)
(Michelson
et al., 2004)
292 ATX
124 PBO
33 10.6 ATX
10.1 PBO
89.4%
male
ATX,
90.3%
male
PBO
73.1%
Combined;
22.4%
inattentive
41.3 15.8 ATX 15.7
PBO
5.2 2.3 ATX
2.2 PBO
ATX (second
randomization)
(Buitelaar
et al., 2007)
81 ATX
82 PBO
33 10.7 ATX
11.0 PBO
88.9%
male
ATX,
90.2%
male
PBO
74.2%
combined;
20.9%
inattentive
41.0 ATX
40.7 PBO
13.4 ATX 12.5
PBO
– –
LDX (Coghill
et al., 2014)
276 51 10.9
average
in open-
label
76.8%
male
80.8%
combined;
16.7%
inattentive
40.7 41.9 LDX 40.2
PBO
4.9 5.1 LDX
5.0 PBO
d-MPH (Arnold
et al., 2004)
35 d-
MPH 40
PBO
7(US
only)
10 d-MPH 77.5%
male
PBO,
85.7%
male d-
MPH
80%
Combined;
20%
inattentive
– – – –
GXR (Newcorn
et al., 2014)
157 GXR
15 PBO
67 10.7 GXR
11.0 PBO
74.3%
male
84.1%
combined;
12.1
inattentive
43.7 43.5 - -
Adults
ATX (Upadhyaya
et al., 2013)
524 152 33.1
average
58.4%
male
72.3%
Combined;
25.4%
inattentive
- - 5.0 4.99
MPH-LA (Huss
et al., 2014)
725 67 35.4
average
54.5%
male
– 39.2 – – –
LDX (Brams
et al., 2012)
116 36 (US
only)
35.8
average
43.1%
male
– 11.2a 10.6 2.1a 2.1
OROS-MPH
(Biederman
et al., 2010)
112
OROS-
MPH
115
PBO
1(US) 34.7
OROS-
MPH
36.4
PBO
52% male – – – – –
OROS-MPH
(Buitelaar
et al., 2012)
155
OROS-
MPH
23
(European
countries)
35.0
OROS-
MPH,
open-
label
54% male 68.4%
Combined;
27.7%
inattentive
– – – –
Abbreviations: ADHD, attention-deﬁcit/hyperactivity disorder; ADHD-RS-IV, ADHD Rating Scale; ATX, atomoxetine; CGI-S, Clinical
Global Impression of Severity scale; GXR, guanfacine extended-release; LDX, lisdexamfetamine dimesylate; d-MPH, dexmethylphe-
nidate hydrochloride; MPH-LA, methylphenidate modiﬁed-release; OROS-MPH, osmotic-release oral system methylphenidate; PBO,
placebo; US, United States; –, not available.
aAt baseline patients were to have had a ADHD-RS-IV scale with Adult Prompts Total Scoreo22. Participants were required to have
received commercially available LDX (30, 50, or 70 mg/day) for Z6 months with an acceptable safety proﬁle.
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Table 2 Summary of ADHD pediatric withdrawal studies – response and relapse deﬁnitions and outcomes.
Study Lead-in period Response cutoff Maintenance
of response
period
Primary
outcome
Relapse deﬁnition Relapse rate
upon
medication
discontinuation
(%)
Relapse rate
with
medication
maintenance
(%)
ATX (First
randomiza-
tion)
(Michelson
et al., 2004)
12-Week (10-week
open-label)
(n=604)
ADHD-RS-IV total score Z25% ↓,
and CGI-S score of 1 or 2 at both
9 and 10 weeks
9-Month
double-blind
(n=416)
Time-to-
relapse over
ﬁrst 9 months.
PBO=146 days;
ATX=218 days
Primary–↑to 90% of ADHD-RS-IV
total score at study entry and Z2-
point↑in CGI-S score at the end of
the 10-week treatment period.
secondary– Z50%↑in ADHD-RS-IV
total score and Z2-point↑in CGI-S
compared to randomization
Primary 37.9%;
secondary 47.6%
Primary
22.3%;
secondary
28.4%
ATX (second
randomiza-
tion)
(Buitelaar
et al., 2007)
1-Year (n=292) Z25%↓in ADHD-RS-IV total score,
and CGI-S score of 1 or 2 after 10
weeks
6-Month
double-blind
(n=163)
Time-to-
relapse for all
randomized
subjects.
PBO=130.8
days;
ATX=160.5
days
Primary–↑to 90% of ADHD-RS-IV
total score at study entry and Z2-
point↑in CGI-S score at the end of
the 10-week treatment period.
Secondary– Z50%↑in ADHD-RS-IV
total score and Z2-point↑in CGI-S
score compared with scores at the
time of second randomization
Primary 12.2%;
secondary 19.5%
Primary 2.5%;
secondary
7.4%
LDX (Coghill
et al., 2014)
26-Week open-
label (n=276)
Final 2 weeks of open-label
patients discontinued if dose
adjustments needed,
experienced unacceptable AEs,
or had an ADHD-RS-IV total score
422 or CGI-S score Z3
6-Week
double-blind
(n=157)
Percentage of
treatment
failures
Z50%↑in ADHD-RS-IV total score
and Z2-point↑in CGI-S score
compared to randomization-
withdrawal period
Primary 67.5% Primary 15.8%
d-MPH (Arnold
et al., 2004)
6-Week open-label
phase (n=89)
Stable dose and CGI-I score of
1 or 2 for ﬁnal 2 weeks of open-
label
2-Week
double-blind
(n=76)
Percentage of
treatment
failures
Primary-treatment failures,
deﬁned as CGI-I score of 6 or
7 relative to visit 8. secondary–
treatment failure CGI-I score=5,
6, or 7
Primary 61.5%;
secondary 71.8%
Primary
17.1%;
secondary
45.8%
GXR (Newcorn
et al., 2014)
7-Week open-label
dose-optimization,
6-week open-label
maintenance of
optimized dose
(n=528)
Z30%↓from visit 2/enrollment in
the ADHD-RS-IV total score and a
CGI-S score of 1 or 2 with
tolerable side effects
26-Week
double-blind,
RWP (n=316)
Percentage of
treatment
failures
Z50%↑in ADHD-RS-IV total score
and a Z2-point increase in CGI-S
score from RWP baseline (visit/
week 13) at 2 consecutive visits
Primary 64.9% Primary 49.3%
Abbreviations: ADHD, attention-deﬁcit/hyperactivity disorder; ADHD-RS-IV, ADHD Rating Scale; AEs, adverse events; ATX, atomoxetine; CGI-I, Clinical Global Impression of Improvement
scale; CGI-S, Clinical Global Impression of Severity scale; GXR, guanfacine extended-release; LDX, lisdexamfetamine dimesylate; d-MPH, dexmethylphenidate hydrochloride; n, number of
patients; PBO, placebo; RWP, randomized withdrawal phase; ↓, decrease; ↑, increase.
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tion) (Michelson et al., 2004). Subjects who maintained
their response to ATX acutely and had completed 1 year of
ATX treatment were re-randomized in double-blind fashion
to continued ATX or to placebo substitution for 6 months
(second randomization) (Buitelaar et al., 2007). In Buitelaar
et al. (2007) and Michelson et al. (2004), relapse was
deﬁned as an increase in ADHD Rating Scale [ADHD-RS-IV]
total score to Z90% of the score at study entry and an
increase of Z2 points in Clinical Global Impression of
Severity (CGI-S) score above the CGI-S score at the end of
the initial 10-week treatment period.
A 26-week, open-label, phase 3 trial evaluated the
efﬁcacy and safety of LDX (30, 50, or 70 mg per day) in
patients with ADHD (6–17 years; N=276) from Europe and
the United States (Coghill et al., 2014). Patients who
completed open-label treatment (n=157) were randomized
1:1 to their optimized dose of LDX (30, 50, or 70 mg/day) or
placebo for a 6-week, randomized withdrawal phase.
Relapse was deﬁned as a Z50% increase in the ADHD-RS-
IV total score and a Z2-point increase in CGI-S score
relative to the start of the randomized withdrawal phase.
Relapse rates in children with ADHD were also analyzed
after treatment with d-MPH (Arnold et al., 2004). After a
6-week, open-label titration of d-MPH (2.5–10.0 mg twice-
daily), relapse was assessed during a randomized, double-
blind, placebo-controlled, 2-week withdrawal period. The
study took place at 7 sites in the United States. Relapse was
deﬁned as treatment failure based on scores of 6 or 7 on the
Clinical Global Impression of Improvement scale (CGI-I)
compared to randomization.
The long-term maintenance of efﬁcacy of GXR (4–7 mg/day)
was studied in children and adolescents (6–17 years) with
ADHD (ADHD-RS-IV total score Z32 and CGI-S score Z4)
(Newcorn et al., 2014) in a multicenter, double-blind, placebo-
controlled, randomized withdrawal study. The study was
conducted at 67 centers in Europe, the United States, and
Canada between May 2010 and June 2013. The study com-
prised 6 time periods: screening and washout; 7-week, open-
label, dose-optimization; 6-week, open-label, maintenance of
optimized dose; 26-week, double-blind, randomized withdra-
wal phase; 2-week, posttreatment taper; and 1-week, safety
follow-up. Study drug (1, 2, 3, or 4 mg GXR) was administered
once-daily; treatment failure was deﬁned as a Z50% increase
in ADHD-RS-IV total score and a Z2-point increase in CGI-S
score at 2 consecutive visits, compared with respective scores
at the double-blind baseline visit (visit 13/week 13), or
discontinuation for any reason.2.3. Studies in adults
In adult patients, studies examining ATX (Upadhyaya et al.,
2013), MPH modiﬁed-release (MPH-LA) (Huss et al., 2014),
LDX (Brams et al., 2012), or osmotic-release oral system
methylphenidate (OROS-MPH) (Biederman et al., 2010;
Buitelaar et al., 2012) were identiﬁed (Table 3).
Maintenance of response with ATX treatment was analyzed
in adults with ADHD during a 25-week, double-blind, placebo-
controlled, randomized withdrawal phase (Upadhyaya et al.,
2013). Only adults who previously responded to 12-week,open-label treatment with ATX and maintained that response
during a randomized, 12-week, double-blind maintenance
period (ATX dose: 80–100 mg/day) were included in the study.
The study was conducted at 152 sites in the European Union
(60%), United States, Mexico, Argentina, and Russia. Relapse
was deﬁned as a return to Z80% of open-label, baseline
Conners' Adult ADHD Rating Scale-Investigator-Rated: Screen-
ing Version (CAARS-Inv:SV) total score after 24 weeks and
2 consecutive visits with a CGI-S score Z4 points.
The maintenance of effect of MPH-LA in adults with ADHD
was evaluated in a 40-week, double-blind, randomized,
placebo-controlled study. The study was conducted at 67
centers in 9 countries. The study consisted of 3 treatment
phases: (1) a 9-week, double-blind, randomized, placebo-
controlled, parallel-group, conﬁrmation phase, (2) a
5-week, real-life dose, optimization phase during which all
patients, including those treated with placebo in the
double-blind dose-conﬁrmation phase, were started on a
dose of 20 mg/day and titrated each week to their optimal
dose, and (3) a 6-month, double-blind, randomized, pla-
cebo-controlled, withdrawal phase to evaluate the main-
tenance of effect of MPH-LA (40, 60, or 80 mg/day) in adults
with ADHD (Huss et al., 2014). Relapse was deﬁned as a
Z30% worsening from randomization and o30% remaining
improvement from ADHD-RS-IV total score at study entry.
The maintenance of effect of LDX (30, 50, or 70 mg/day)
was examined in a double-blind, multicenter, placebo-
controlled, randomized withdrawal study consisting of
4 phases (Brams et al., 2012). The study was conducted at
36 sites in the United States. At the end of the open-label
treatment phase, participants entered a 6-week, double-
blind, randomized, withdrawal phase and were assigned to
treatment with LDX or placebo. Relapse was deﬁned as a
Z50% increase in ADHD-RS-IV total score and a Z2-point
increase in CGI-S score.
The maintenance of effect of OROS-MPH was examined in
2 studies (Biederman et al., 2010; Buitelaar et al., 2012). The
ﬁrst study was a 3-phase, double-blind, placebo-controlled,
parallel study in adult patients with ADHD, (Biederman et al.,
2010) containing a 6-week, acute efﬁcacy phase (mean daily
dose: OROS-MPH 0.9770.32 mg/kg), followed by a 24-week,
double-blind, continuation phase for treatment responders,
and a 4-week, double-blind, placebo-controlled, discontinua-
tion phase. The study was conducted at a site in the United
States. Relapse was deﬁned as a Z2-point increase in CGI-I
score from the end of acute treatment oro15% improvement
on the Adult ADHD Investigator Symptom Rating Scale (AISRS)
for 2 consecutive visits.
In the second study, OROS-MPH (18, 36, 54, or 72 mg/day)
was evaluated open-label for 52 weeks in patients who had
previously completed a short-term, placebo-controlled trial
and a short-term, open-label extension (Buitelaar et al.,
2012). The study was conducted at 23 European sites.
Patients completing 52 weeks of treatment were eligible
for a 4-week, placebo-controlled, randomized withdrawal
phase in which loss of treatment effect was assessed using
the Conners' Adult ADHD Rating Scale-Observer-Rated:
Screening Version (CAARS-O:SV) and CGI-S scores. Relapse
was deﬁned as an increase (worsening) of 450% from
baseline in CAARS-O:SV total score or a Z2-point increase
in CGI-S score from randomization.
Table 3 Summary of ADHD adult withdrawal studies – response and relapse deﬁnitions and outcomes.
Study Lead-in period Response cutoff Maintenance
of response
period
Primary outcome Relapse deﬁnition Relapse rate
upon
medication
discontinuation
(%)
Relapse rate
with
medication
maintenance
(%)
ATX
(Upad-
hyaya
et al.,
2013)
24-Week (12 weeks open-label
followed by 12 weeks of
maintenance)(n=2017)
Z30% Improvement in
CAARS-Inv-SV total score
and CGI-S score r3
maintained through the
maintenance phase (1
excursion allowed)
25-Week
double-blind,
RWP (n=524)
Maintenance of
response (%
with↓Z30% baseline
CAARS-Inv-SV total
score and CGI-S score
r3 (2
nonconsecutive
excursions allowed)
2 Consecutive visits with
CGI-S score Z4 and return
to Z80% of original
baseline CAARS-Inv-SV
total score
Primary 7.4% Primary 2.3%
MPH-LA
(Huss
et al.,
2014)
5–14 Weeks (9-week PBO-
controlled, double-blind
period of 3 doses followed by
5-week period of patients'
doses titrated to optimal dose
with at least 1-week stable
dose)(n=725)
Z30% ↓ADHD-RS-IV total
score by end of 5-week
dose-optimization phase
6-Month
double-blind
(n=489)
% Treatment failure
using logistic
regression
Z30% Worsening from
randomization and o30%
remaining improvement
from original baseline on
ADHD-RS-IV total score
Primary 49.6% Primary 21.3%
LDX (Brams
et al.,
2012)
Retrospective 6-month period
and prospective 3-week open-
label period (n=123)
Stable dose in
retrospective and
prospective periods.
Patients who had AHDH-
RS-IV score Z22 or CGI-S
score 43 at visit 3 were
withdrawn from the study.
6-week
double-blind
(n=116)
Rate of relapse 50%↑in ADHD-RS-IV total
score and Z2-point↑in
CGI-S score
Primary 75.0% Primary 8.9%
OROS-MPH
(Bieder-
man
et al.,
2010)a
6-Week PBO-controlled
double-blind efﬁcacy,
responders 24 week double-
blind maintenance (n=227)
CGI-I score r2 and
AISRS↑430% from baseline
4-Week
double-blind
(n=23)
Rate of relapse CGI-I score Z2-point↑from
the end of phase 1 or
o15% improvement on
AISRS for 2 consecutive
visits
Primary 18% Primary 0%
OROS-MPH
(Buitelaar
et al.,
2012)
5-Week double-blind PBO-
controlled study (n=355)
followed by open-label OROS-
MPH for minimum exposure of
52 weeks (n=155)
Completers of initial
7-week open-label phase
and those with 4 weeks
stable dose at end of
open-label
4-Week
double-blind
RWP (n=45,
99 completed
the open-
label, but only
45 consented)
Worsening in mean
CAARS-O:SV score.
Not signiﬁcant. Both
arms had mean
worsening from
baseline.
Primary:↑(worsening) of
450% from baseline in
CAARS-O:SV total score.
Secondary: Z2-point↑in
CGI-S score from
randomization or
discontinued for lack of
efﬁcacy
Primary 36.4%
secondary 41%
Primary 26.1%
secondary
25%
Abbreviations: ADHD, attention-deﬁcit/hyperactivity disorder; ADHD-RS-IV, ADHD Rating Scale; AISRS, Adult ADHD Investigator Symptom Rating Scale; ATX, atomoxetine; CAARS-Inv:SV,
Conners' Adult ADHD Rating Scale-Investigator-Rated: Screening Version; CAARS-O:SV, Conners' Adult ADHD Rating Scale-Observer-Rated: Screening Version; CGI-I, Clinical Global
Impression of Improvement scale; CGI-S, Clinical Global Impression of Severity scale; LDX, lisdexamfetamine dimesylate; MPH-LA, methylphenidate modiﬁed-release; n, number of
patients; OROS-MPH, osmotic-release oral system methylphenidate; PBO, placebo; RWP, randomized withdrawal phase; ↓, decrease; ↑, increase.
aNot included in the current analyses because did not demonstrate maintenance of response.
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analysis, as they were not able to demonstrate maintenance
of response (Biederman et al., 2010; Buitelaar et al., 2012).
2.4. Statistical analyses
Data from ATX studies – in children and adolescents
(Buitelaar et al., 2007; Michelson et al., 2004) and in adults
(Upadhyaya et al., 2013) – were analyzed. The primary
deﬁnition of relapse in the study of children and adolescents
treated with ATX was an increase to 90% of ADHD-RS-IV total
score at study entry and a Z2-point increase in CGI-S score.
The primary deﬁnition of relapse used in the adult study of
ATX was 2 consecutive visits with a CGI-S score of Z4 and
return to Z80% of original baseline CAARS-Inv:SV total
score. As shown in Tables 2 and 3, the deﬁnition of relapse
varied among studies. Hence, for appropriate indirect
comparison in children and adolescents, ATX data were re-
analyzed according to a post-hoc deﬁnition of relapse that
most closely mirrored those in stimulant and guanfacine
trials (Z50% increase in ADHD-RS-IV total score and a Z2-
point increase in CGI-S score from randomization observed
at 1 visit). This post-hoc deﬁnition of relapse is referred to
as a secondary deﬁnition of relapse.
Time-to-relapse was analyzed in the ATX trials using
Kaplan–Meier survival analysis and compared between
groups using the Wilcoxon test (for the ATX study in children
and adolescents) and the log-rank test (for the ATX study in
adults). The Wilcoxon test was planned for the ATX study in
children and adolescents because it was the ﬁrst relapse
prevention ATX trial (Michelson et al., 2004) and it was
expected at the time that relapse would occur earlier
rather than later, which was an appropriate assumption
for the Wilcoxon test. For the ATX study in adults
(Upadhyaya et al., 2013), based on the observations from
the study in children and adolescents, the log-rank test was
speciﬁed to require less assumption of the type of relapse
patterns that would be observed.
3. Results
3.1. Studies in children and adolescents
A summary of ADHD pediatric withdrawal studies' response
and relapse deﬁnitions and outcomes are shown in Table 2.
In the ATX trial, relapse upon discontinuation, deﬁned as a
return to 90% of baseline ADHD-RS-IV total score at study
entry and a Z2-point increase in CGI-S score, was seen in
37.9% of patients in the ﬁrst randomization (9-month
double-blind phase) and 12.2% of patients in the second
randomization (6-month double-blind continuation). When
relapse was deﬁned as a Z50% increase in ADHD-RS-IV total
score and a Z2-point increase in CGI-S score compared to
ﬁrst and second randomization, relapse upon discontinua-
tion was seen in 47.6% of patients in the ATX trial ﬁrst
randomization (after responding to ATX for 10 weeks) and
19.5% of patients in the second randomization (after
responding to ATX for almost 1 year). In the LDX trial,
67.5% of patients showed relapse 6 weeks after discontinua-
tion. In the d-MPH trial, 61.5% of patients showed relapse
deﬁned as a CGI-I score of 6 or 7 relative to visit 8, afterresponding to d-MPH for 6 weeks, and 71.8% of patients
showed relapse deﬁned as a CGI-I score of 5, 6, or 7, after
the 2-week withdrawal phase. In the GXR trial, 64.9% of
patients showed relapse after responding to GXR for
13 weeks.
Relapse rates upon medication discontinuation in children
previously responsive and stable on treatment are shown in
Figure 1. The percentage of children and adolescents
relapsing after approximately 1 year of ATX treatment is
shown in Figure 2; relapse is deﬁned as a Z50% increase in
ADHD-RS-IV total score and a Z2-point increase in CGI-S
score. A gradual increase in relapse over time (25 weeks or
180 days) was observed.
3.2. Studies in adults
A summary of ADHD adult withdrawal studies' response and
relapse deﬁnitions and outcomes is shown in Table 3. In the
ATX trial, relapse upon discontinuation was deﬁned as
2 consecutive visits with a CGI-S score Z4 and a return
to Z80% of original baseline CAARS-Inv:SV total score.
Relapse upon discontinuation was seen in 7.4% of patients
25 weeks after discontinuation. In the MPH-LA trial, after a
6-month discontinuation, 49.6% of patients showed relapse
upon discontinuation, deﬁned as Z30% worsening from
randomization and o30% remaining improvement from
ADHD-RS-IV total score at study entry. In the LDX trial,
relapse was deﬁned as a Z50% increase in ADHD-RS-IV total
score and a Z2-point increase in CGI-S score, and relapse
was seen in 75.0% of patients 6 weeks after discontinuation.
Relapse upon medication discontinuation in adults pre-
viously responsive and stable on ATX or stimulant treatment
is shown in Figure 3. The percentage of patients relapsing
after approximately 25 weeks of ATX treatment is shown in
Figure 4; relapse is deﬁned as a Z30% increase in CAARS-
Inv:SV total score. Over time (180 days) the percentage of
patients relapsing steadily increased for placebo compared
to ATX.
4. Discussion
Treatment with ATX (among patients who previously
responded to medication) was associated with a low rate
of relapse after discontinuation of treatment. Persistent
symptom relief, even upon treatment discontinuation, may
be the result of lasting neurobiological changes and/or
behavioral changes associated with consolidation of treat-
ment effects (Fumagalli et al., 2010; Udvardi et al., 2013).
In a study of the rat brain, 2 months after ﬁnal drug
exposure, ATX was shown to affect transcription/translation
of the N-methyl-D-aspartate (NMDA) receptor and the
norepinephrine transporter in vivo (Udvardi et al., 2013).
In adolescent spontaneously hypertensive rats, subchronic
exposure to ATX was shown to increase brain-derived
neurotrophic factor (BDNF) expression and signaling in the
prefrontal cortex, whereas MPH reduced it. In addition,
MPH but not ATX increased BDNF messenger RNA in the
striatum and nucleus accumbens (Fumagalli et al., 2010).
The data presented here raise the possibility of differ-
ences in the neurobiological effects of stimulants and ATX in
humans (both adults and children) as well (Bush et al., 2013;
Figure 2 Long-term ADHD relapse prevention study in children
and adolescents: relapse after approximately 1 year of atomox-
etine treatment. The graph shows data up to 25 weeks
(approximately 180 days). The mean days to relapse were 171
days for atomoxetine and 146 days for placebo. Abbreviation:
J. Buitelaar et al.1618Schulz et al., 2012). Regional similarities and differences in
the way stimulants and ATX affect brain activity in adults
after 6 weeks of treatment have been shown with functional
magnetic resonance imaging (fMRI) (Bush et al., 2013). Both
stimulants and ATX signiﬁcantly increased activation in
cortical and subcortical regions that subserve attention
and executive function. However, activation of the dorsal
anterior cingulate cortex was unique to ATX, and activation
of the striatum was unique to MPH. These differential
effects could potentially contribute to the differences in
relapse seen across treatment types, but the speciﬁc
manner in which differential activation of brain regions
leads to these clinical changes is not clear. Interestingly,
even though both MPH and ATX were associated with similar
improvements in ADHD symptoms and response inhibition on
the go/no-go test, there were differential activations in the
right inferior frontal gyrus, left anterior cingulate, supple-
mentary motor area, and bilateral posterior cingulate
cortex (Schulz et al, 2012).
In a fMRI study with healthy volunteers who received a
single dose of MPH or ATX before performing a rewarded
working memory task, MPH and ATX had differential effects
on activated and deactivated networks, although the
effects of MPH and ATX were qualitatively similar
(Marquand et al., 2011). MPH produced greater activity in
working memory networks (the ability to hold and manip-
ulate information for future action), and ATX produced
greater activity in the default mode network. MPH
enhanced task-related deactivations more than ATX,
whereas ATX attenuated working memory networks more
than MPH. Thus, interactions between drug effects and
motivational state may be important in deﬁning the effects
of MPH and ATX.
The initial response deﬁnition was different among
studies, and the studies used different deﬁnitions of
relapse. We tried to correct for the differences in relapseFigure 1 Relapse upon medication discontinuation in children p
stimulant treatment. Relapse was deﬁned as an increase to 50%
compared to randomization. ATX data were re-analyzed and patients
patients had to meet identical relapse criteria at 2 consecutive v
period, n=27); d-MPH (2-week withdrawal period, n=24); LDX (6-we
n=98). The data are from the following distinct studies: d-MPH (Arno
2014); ATX (Buitelaar et al., 2007; Michelson et al., 2004). Abbrevia
IV, ADHD Rating Scale; ATX, atomoxetine; CGI-S, Clinical Global
guanfacine extended-release; LDX, lisdexamphetamine dimesylate;deﬁnitions by reanalyzing the ATX studies in a manner that
was similar to the stimulant and GXR studies. The length of
the withdrawal period was the same or longer for ATX
compared with the stimulant and GXR studies.4.1. Clinical implications
In general, continuous treatment of ADHD is recommended;
for patients who have treatment response for a short time,
treatment should be continued as long as it remains
clinically effective (National Institute for Health and
Clinical Excellence [NICE], 2008). In patients who are
stable, treatment should be reviewed annually, assessing
clinical need, beneﬁts, and side effects. In patients who did
not have severe problems at baseline (e.g., legal problems,
history of severe impulsivity) that could become worse uponreviously responsive and stable on long-term atomoxetine or
of ADHD-RS-IV total score and a Z2-point increase in CGI-S
had to meet relapse criteria at 1 visit (in Buitelaar et al., 2007;
isits). ATX (2-week, n=2; 6-week, n=12; 6-month withdrawal
ek withdrawal period, n=52); GXR (26-week withdrawal period,
ld et al., 2004); GXR (Newcorn et al., 2014); LDX (Coghill et al.,
tions: ADHD, attention-deﬁcit/hyperactivity disorder; ADHD-RS-
Impression of Severity scale; CI, conﬁdence interval; GXR,
d-MPH, dexmethylphenidate hydrochloride.
ADHD, attention-deﬁcit/hyperactivity disorder.
Figure 3 Relapse upon medication discontinuation in adults previously responsive and stable on long-term atomoxetine or
stimulant treatment. Relapse deﬁned as an increase to 50% of CAARS-Inv:SV total score and a Z2-point increase in CGI-S score
compared to randomization. The labeling indicates the length of the withdrawal period after stopping the referenced medication.
ATX (6-week withdrawal period, n=23; 6-month withdrawal period, n=41); MPH-LA (6-month withdrawal period, n=57); LDX
(6-week withdrawal period, n=45). The data are from the following distinct studies: MPH-LA (Huss et al., 2014); LDX (Brams et al.,
2012); ATX (Upadhyaya et al., 2013). Abbreviations: ATX, atomoxetine; CAARS-Inv:SV, Conners' Adult ADHD Rating Scale-Investigator-
Rated: Screening Version; CGI-S, Clinical Global Impression of Severity scale; CI, conﬁdence interval; LDX, lisdexamphetamine
dimesylate; MPH-LA, methylphenidate modiﬁed-release.
Figure 4 ADHD maintenance of response (withdrawal) study in
adults: relapse after approximately 24 weeks of atomoxetine
treatment. The graph shows data up to 25 weeks (approxi-
mately 180 days).
1619ADHD response upon medication discontinuationtreatment discontinuation, the need for continuing treat-
ment should be periodically assessed, as indicated in the
United Kingdom summary of product characteristics for ATX
(Eli Lilly and Company Limited, 2013).
When making treatment decisions about patients who are
responding well to treatment, it is important to set
accurate expectations after discontinuation. If patients
decide to discontinue, they should continue to be evaluated
to assess initial relapse symptoms.
The differences in the mechanism of action between
stimulants and ATX may lead to a lower percentage of
relapse upon discontinuation of treatment with ATX. Onset
of efﬁcacy may be slower with ATX compared with stimu-
lants; however, responders (after long-term maintenance)
may be able to maintain response upon discontinuation
much longer. In Figures 2 and 4 the percentage of patients
relapsing slowly increases over time compared to the
relapse patterns seen with other stimulant and nonstimu-
lant medications which increase quickly after discontinua-
tion (Brams et al., 2012; Coghill et al., 2014; Newcornet al., 2014). This effect may be due to more than the
gradual ATX offset of effect, because relapse upon discon-
tinuation tends to happen beyond the 12-week mark.
Atomoxetine may be unique even among nonstimulants,
considering that GXR, another nonstimulant, appears to
have a higher percentage of relapse and a more rapid
relapse rate, which are more similar to stimulant
medication.
4.2. Limitations
The following limitations need to be considered when
interpreting the data presented here. No head-to-head
comparisons were performed, and differences across study
populations included geography, ethnicity, comorbidity, and
duration of disorder. Unknown study design effects are a
potential limitation, and design differences among studies
were present (e.g., duration of the study, deﬁnition of
relapse, length of withdrawal period, initial response deﬁ-
nition, time of lead-in period). Comparisons here are made
between long-term treatment with ATX and a mixture of
long-term and shorter-term treatments with stimulants and
GXR, and these differences in treatment time before
medication withdrawal can inﬂuence the reported relapse
rates. In addition to differences in the neurobiological
effects of stimulants and ATX, several possible factors
related to the clinical trials may have contributed to the
differences in observed percentages of relapse for ATX
versus stimulants. Patient population differences among
the studies can contribute to the observed differences (i.
e., studies differed in the geography, ethnicity, comorbidity,
and duration of the disorder). In studies with stimulants,
due to quicker onset, the patients may “feel” a stimulant
more (including withdrawal) which may cause the time-to-
randomization not to be truly blind. The duration of the
study and the availability of other treatments could also
affect the outcome of the study. It is possible that the
population of responders in the ATX studies includes a
J. Buitelaar et al.1620higher than expected percentage of (unknown/hidden)
placebo responders giving rise to low relapse percentages.
Additionally, the ATX study in adults examined relapse in a
highly selected subpopulation that responded to treatment
with ATX and was compliant with the lengthy study proto-
col. Patients who responded poorly to treatment with ATX
and displayed fewer behavioral adaptations before rando-
mization might have displayed higher relapse rates after
discontinuation of treatment with ATX, but these patients
were likely eliminated from the study due to the response
criteria that had to be met before re-randomization for the
withdrawal phase. Another explanation could be that there
is an increased unintentional “unblinding” of stimulants due
to more obvious immediate effects, although this is not
sufﬁcient to explain such large differences over the long
duration of the ATX studies.
4.3. Conclusion
The percentage of relapse at each time point studied after
discontinuing stimulants and GXR appears substantially
higher than observed when discontinuing ATX, suggesting
longer maintenance of response after discontinuing ATX
than after stimulants and GXR. When these results for ATX
are viewed in the context of results for other medications,
it is important to consider whether differences in mechan-
ism of action may lead to differential effects at time of
treatment discontinuation. In addition, relapse over time
appears more rapid for discontinuation from stimulants and
GXR, and more gradual for discontinuation from ATX.
Additional research, including head to head studies, are
needed to better understand the relapse of ADHD symptoms
and the neurobiological basis of relapse after medication
discontinuation.
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